Global Molecular Cytogenetics Market 2021 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Molecular Cytogenetics Market 2021 (Includes Business Impact of COVID-19)
Global Molecular Cytogenetics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global molecular cytogenetics market report has been segmented as per product type, technique type, end-user, application, and region.
Request Covid - 19 Impact
The global Molecular Cytogenetics market size was valued at USD$7.23 billion in 2020 and is projected to reach $19.67 billion by 2030, and is anticipated to expand at a CAGR of 7.13% over the forecast period from 2020 to 2030.


Global Molecular Cytogenetics Market: Overview


Molecular cytogenetics includes all aspects of various applications of chromosome biology and molecular cytogenetic techniques in a wide range of medicine and biology. This includes the functional and structural organization of the nucleus and chromosome, expression and evolution, genome variation, and chromosome abnormalities mainly in tumor genetics and medical genetics. Molecular cytogenetics is a beneficial method for the treatment and diagnosis of various malignant tumors such as brain tumors, cancer, hematological malignancies, etc. The molecular cytogenetics is very important applications in the fields of medicine and biology.


Global Molecular Cytogenetics Market: Dynamics


Rising prevalence of cancer, the subsequent requirement for the accurate diagnosis, and the increasing necessity for the development of advanced technologies for a comprehensive understanding of cancer at a genomic level across the globe. These aforesaid are some major factors forecasted to drive growth of the target market over the forecast period. In addition, rising preference for various cytogenetic techniques among healthcare sector such as Comparative Genomic Hybridization (CGH), Fluorescence in Situ Hybridization (FISH), and others as they provide detailed information about cancer-related molecular signatures. This is a key factor projected to fuel the global molecular cytogenetics market growth during the forecast period.

Increasing adoption of various cytogenetic tools for pharmacogenomic biomarker studies and increasing technological advancements in FISH and CGH techniques are other factors expected to boost growth of the global market. In addition, increasing penetration of various molecular cytogenetics products such as consumables, software and services, instruments, and reagents and kits across the globe is key factor projected to propel growth of the global molecular cytogenetics market.

However, lack of coverage and reimbursement policies for genomic tools in the personalized care application is key factor forecasted to hamper growth of the global molecular cytogenetics market. In addition, less availability of skilled professionals across the globe and high cost associated with the molecular cytogenetic techniques are challenging factors that may affect growth of the target market.


Global Molecular Cytogenetics Market: Segment Analysis


Increasing preference for effective molecular cytogenetic techniques for thorough cancer studies is the primary factor driving revenue growth of the oncology segment among the application segments.

Among the end-user segment, the clinical and research laboratories segment is projected to witness the highest growth in the global molecular cytogenetics market, owing to rising implementation of molecular cytogenetic techniques in clinical discovery.


Global Molecular Cytogenetics Market: Region Analysis


The North America molecular cytogenetics market contributes the largest market share in terms of revenue in the global market, owing to the high presence of research and academic institutes and clinical research laboratories in the countries such as Canada and US in this region. The market in the Asia Pacific is projected to register the fastest growth in the global market followed by the market in Europe, owing to high healthcare expenditure, rising number of scientific researches, and high awareness about advanced therapies and diagnostics in many countries in these regions. The market in Latin America and Middle East & Africa are forecasted to witness steady growth in the global market, owing to rising new players in the countries in these regions.

Global Molecular Cytogenetics Market Segmentation:

Segmentation by Product Type:

  
Reagents and Kits
  
Instruments
  
Consumables
  
Software & Services

Segmentation by Technique Type:

  
Fluorescence in Situ Hybridization (FISH)
  
Comparative Genomic Hybridization (CGH)
  
Array-based comparative genomic hybridization
  
Standard comparative genomic hybridization
  
Karyotyping
  
Immunohistochemistry

Segmentation by End-user:

  
Clinical and Research Laboratories
  
Pharmaceutical and Biotechnology Companies
  
Research and Academic Institutes
  
Diagnostic Centers
  
Hospitals

Segmentation by Application:

  
Oncology
  
Genetic Disorders
  
Personalized Medicine


Key Market Players included in the report:


  
Abbott Laboratories (US)
  
Agilent Technologies (US)
  
Applied Spectral Imaging (US).
  
ARUP Laboratories;
  
Bio-Rad Laboratories (US)
  
Calgary Laboratory Services
  
Danaher Corporation (US)
  
F. Hoffmann-La Roche Ltd. (Switzerland)
  
Genesis Laboratories Inc.
  
Illumina Inc. (US)
  
Integrated Systems Engineering S.r.l.
  
Neogenomics
  
OHSU School of Medicine-Molecular and Medical Genetics
  
Oxford Gene Technology (UK)
  
PerkinElmer Inc. (US)
  
Thermo Fisher Scientific Inc. (US)
  
UCLA Health - UCLA Pathology and Laboratory Medicines
  
UW Cytogenetic Services
  
Virtual Scientific
  
Weill Cornell Medicine
  
WiCell Research Institute Inc.


Below are the key development related to Molecular Cytogenetics Market in 2020 and 2021.


August 2020: Bionano Genomics acquires Lineagen for $9.6M in cash, shares and liabilities Bionano Genomics announced that it has acquired Lineagen, a Salt Lake City, Utah based genetic diagnostic company. Bionano said it aims to revolutionize clinical genome testing and genomics research by making comprehensive structural variation analysis a routine process that is accurate, streamlined, efficient and cost effective. Lineagen specializes in pediatric neurodevelopmental disorders, including autism spectrum disorder and developmental delay, and has developed proprietary technology and commercialized multiple laboratory developed tests, or LDTs. With the acquisition of Lineagen, Bionano adds CLIA-certified diagnostic testing services along with expertise in commercializing cytogenetic assays, genetic counseling, third party payor contracts and reimbursement. Source